"CD40 Antigens" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Members of the tumor necrosis factor receptor superfamily with specificity for CD40 LIGAND. They are found on mature B-LYMPHOCYTES, some EPITHELIAL CELLS; and lymphoid DENDRITIC CELLS. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centers. Mutations in the CD40 antigen gene result in HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 3. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
| Descriptor ID |
D019013
|
| MeSH Number(s) |
D12.776.543.750.705.852.760.097 D23.050.301.264.051.140 D23.101.100.150.140
|
| Concept/Terms |
CD40 Antigens- CD40 Antigens
- TNFRSF5 Receptor
- Receptor, TNFRSF5
- CDw40 Antigen
- Antigen, CDw40
- Tumor Necrosis Factor Receptor Superfamily, Member 5
- CD40 Antigen
- Antigen, CD40
- Antigens, CD40
|
Below are MeSH descriptors whose meaning is more general than "CD40 Antigens".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Receptors, Cytokine [D12.776.543.750.705.852]
- Receptors, Tumor Necrosis Factor [D12.776.543.750.705.852.760]
- CD40 Antigens [D12.776.543.750.705.852.760.097]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, Differentiation, B-Lymphocyte [D23.050.301.264.051]
- CD40 Antigens [D23.050.301.264.051.140]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, Differentiation, B-Lymphocyte [D23.101.100.150]
- CD40 Antigens [D23.101.100.150.140]
Below are MeSH descriptors whose meaning is more specific than "CD40 Antigens".
This graph shows the total number of publications written about "CD40 Antigens" by people in this website by year, and whether "CD40 Antigens" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 2 | 0 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 2 | 1 | 3 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 5 | 2 | 7 |
| 2018 | 3 | 4 | 7 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "CD40 Antigens" by people in Profiles.
-
Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques. Nat Commun. 2021 09 01; 12(1):5215.
-
Designed proteins assemble antibodies into modular nanocages. Science. 2021 04 02; 372(6537).
-
Platelet and Vascular Biomarkers Associate With Thrombosis and Death in Coronavirus Disease. Circ Res. 2020 09 11; 127(7):945-947.
-
Inhaled steroids associated with decreased macrophage markers in nonasthmatic individuals with sickle cell disease in a randomized trial. Ann Hematol. 2019 Apr; 98(4):841-849.
-
TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs. J Clin Invest. 2018 10 01; 128(10):4387-4396.
-
Characterization of grass carp CD40 and CD154 genes and the association between their polymorphisms and resistance to grass carp reovirus. Fish Shellfish Immunol. 2018 Oct; 81:304-308.
-
Differential cell-intrinsic regulations of germinal center B and T cells by miR-146a and miR-146b. Nat Commun. 2018 07 16; 9(1):2757.
-
Work in Progress: Drugs in Development. Clin Liver Dis. 2018 08; 22(3):501-515.
-
Switching from abacavir to tenofovir disoproxil fumarate is associated with rises in soluble glycoprotein VI, suggesting changes in platelet-collagen interactions. AIDS. 2018 04 24; 32(7):861-866.
-
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect. 2018 Jun; 24 Suppl 2:S83-S94.